Cancer Network Staff

Pembrolizumab failed to produce clinical responses in patients with recurrent or metastatic medullary thyroid cancer, regardless of prior GI-6207 exposure.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

Researchers highlight the importance of geriatric assessments and patient-centered outcomes to manage unique physiological and functional challenges in older breast cancer survivors.

Following the 2022 ASH Annual Meeting and Exposition, Peter Voorhees, MD; Amrita Krishnan, MD; and Josh Richter, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in blood cancer, as well as what research needs more follow-up.

Following the 2022 ASH Annual Meeting and Exposition, Nakhle Saba, MD; Lindsey Roeker, MD; Javier Pinilla, MD, PhD; and Catherine C. Coombs, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in chronic lymphocytic leukemia and lymphoma, as well as what research needs more follow-up.

Adults with previously treated unresectable or metastatic non–small cell lung cancer whose tumors harbor HER2 mutations may now be treated with fam-trastuzumab deruxtecan-nxki.

Expert panelists focus on the treatment of metastatic urothelial cancer and discuss strategies and challenges for maintenance therapy.

Following 2022 ASCO GU, Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, engage in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics include most surprising new data, what needs follow-up, and shameless plug.

Around the Practice: Metastatic Castrate Resistant Prostate Cancer

Around the Practice: High-Risk Renal Cell Carcinoma

Patients with extensive-stage small cell lung cancer show greater response when atezolizumab is added to carboplatin and etoposide versus placebo in the IMpower133 trial.

Register for CancerNetwork's live, interactive event featuring leaders in oncology reviewing and discussing patient cases in breast cancer.